Palatin Technologies, Inc. (0KF3.L) LSE
13.60
-1.2(-8.11%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Palatin Technologies, Inc.
Address
Cedar Brook Corporate Center
Cranbury, NJ 08512
United States of America (the)
Phone
609 495 2200
Website
Sector
Healthcare
Industry
Biotechnology
Employees
30
First IPO Date
January 29, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Carl Spana | Co-Founder, President, Chief Executive Officer & Director | 738,500 | 1962 |
| Stephen T. Wills | Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer & Secretary | 687,960 | 1957 |
| Stephen A. Slusher | Chief Legal Officer | 0 | N/A |
| Michael Raizman | Chief Medical Officer | 0 | N/A |
| John Dodd | Senior Vice President of Preclinical Development | 0 | N/A |
| Robert Jordan | Senior Vice President of Program Operations | 0 | N/A |
| Burns McClellan | Vice President of Investor Relations | 0 | N/A |
| James E. Hattersley | Senior Vice President of Business Development | 0 | 1960 |
Description
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
